Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BREKIYA ® safely and effectively. See full prescribing information for BREKIYA®. BREKIYA® (dihydroergotamine mesylate) injection, for subcutaneous use Initial U.S. Approval: 1946
Medication labelWhy this: Advisory · dailymed-prescription
BREKIYA is indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults. Limitations of Use BREKIYA is not indicated for the preventive treatment of migraine. BREKIYA is not indicated for the management of hemiplegic migraine or migraine with brainstem aura.
- generic_name
- dihydroergotamine mesylate
- product_names
- Dihydroergotamine Mesylate
- ndc
- 64896-509, 64896-509-01, 64896-509-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en